The BeSt story: on strategy trials in rheumatoid arthritis

N.B. Klarenbeek, C.F. Allaart, P.J.S.M. Kerstens, T.W. Huizinga, B.A.C. Dijkmans

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose of review To give an overview of recent strategy trials for the treatment of rheumatoid arthritis. Recent findings Strategy studies showed a clear benefit of dynamic result-driven treatment towards tight control of disease activity compared with 'usual care' in rheumatoid arthritis patients. In addition, treatment given after short symptom duration gives better outcomes than later initiation of treatment. In many trials, combination therapies, especially combinations with prednisolone or biologicals, were superior to monotherapies. Moreover, combination therapies were more effective if given early in the disease as compared with a delayed introduction, giving support to the window of opportunity hypothesis. In the BeSt study, initial combination therapy could be successfully discontinued in half. of the patients, emphasizing that 'initial' would mean 'temporary'. Less evidence is available about initial combination in comparison with combination therapy with a shorter delay. Larger tight-controlled, goal-steered, dynamic strategy trials comparing initial combination therapy with a short-delay combination therapy will help to translate the use of initial (temporary) combination therapy into normal daily practice. Summary Treatment strategy trials have demonstrated that in the majority of patients with rheumatoid arthritis, the following approach is the most beneficial: goal-steered, dynamic treatment towards tight control of disease activity, including early introduction of (an) effective disease-modifying antirheumatic drug(s) in combination with prednisone or antitumor necrosis factor, which includes tapering of the medication if remission or low disease activity is achieved
Original languageUndefined/Unknown
Pages (from-to)291-298
JournalCurrent Opinion in Rheumatology
Volume21
Issue number3
DOIs
Publication statusPublished - 2009

Cite this

Klarenbeek, N.B. ; Allaart, C.F. ; Kerstens, P.J.S.M. ; Huizinga, T.W. ; Dijkmans, B.A.C. / The BeSt story: on strategy trials in rheumatoid arthritis. In: Current Opinion in Rheumatology. 2009 ; Vol. 21, No. 3. pp. 291-298.
@article{be07c5b3baef43b5aa8a0cb727945dcc,
title = "The BeSt story: on strategy trials in rheumatoid arthritis",
abstract = "Purpose of review To give an overview of recent strategy trials for the treatment of rheumatoid arthritis. Recent findings Strategy studies showed a clear benefit of dynamic result-driven treatment towards tight control of disease activity compared with 'usual care' in rheumatoid arthritis patients. In addition, treatment given after short symptom duration gives better outcomes than later initiation of treatment. In many trials, combination therapies, especially combinations with prednisolone or biologicals, were superior to monotherapies. Moreover, combination therapies were more effective if given early in the disease as compared with a delayed introduction, giving support to the window of opportunity hypothesis. In the BeSt study, initial combination therapy could be successfully discontinued in half. of the patients, emphasizing that 'initial' would mean 'temporary'. Less evidence is available about initial combination in comparison with combination therapy with a shorter delay. Larger tight-controlled, goal-steered, dynamic strategy trials comparing initial combination therapy with a short-delay combination therapy will help to translate the use of initial (temporary) combination therapy into normal daily practice. Summary Treatment strategy trials have demonstrated that in the majority of patients with rheumatoid arthritis, the following approach is the most beneficial: goal-steered, dynamic treatment towards tight control of disease activity, including early introduction of (an) effective disease-modifying antirheumatic drug(s) in combination with prednisone or antitumor necrosis factor, which includes tapering of the medication if remission or low disease activity is achieved",
author = "N.B. Klarenbeek and C.F. Allaart and P.J.S.M. Kerstens and T.W. Huizinga and B.A.C. Dijkmans",
year = "2009",
doi = "10.1097/BOR.0b013e32832a2f1c",
language = "Undefined/Unknown",
volume = "21",
pages = "291--298",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

The BeSt story: on strategy trials in rheumatoid arthritis. / Klarenbeek, N.B.; Allaart, C.F.; Kerstens, P.J.S.M.; Huizinga, T.W.; Dijkmans, B.A.C.

In: Current Opinion in Rheumatology, Vol. 21, No. 3, 2009, p. 291-298.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The BeSt story: on strategy trials in rheumatoid arthritis

AU - Klarenbeek, N.B.

AU - Allaart, C.F.

AU - Kerstens, P.J.S.M.

AU - Huizinga, T.W.

AU - Dijkmans, B.A.C.

PY - 2009

Y1 - 2009

N2 - Purpose of review To give an overview of recent strategy trials for the treatment of rheumatoid arthritis. Recent findings Strategy studies showed a clear benefit of dynamic result-driven treatment towards tight control of disease activity compared with 'usual care' in rheumatoid arthritis patients. In addition, treatment given after short symptom duration gives better outcomes than later initiation of treatment. In many trials, combination therapies, especially combinations with prednisolone or biologicals, were superior to monotherapies. Moreover, combination therapies were more effective if given early in the disease as compared with a delayed introduction, giving support to the window of opportunity hypothesis. In the BeSt study, initial combination therapy could be successfully discontinued in half. of the patients, emphasizing that 'initial' would mean 'temporary'. Less evidence is available about initial combination in comparison with combination therapy with a shorter delay. Larger tight-controlled, goal-steered, dynamic strategy trials comparing initial combination therapy with a short-delay combination therapy will help to translate the use of initial (temporary) combination therapy into normal daily practice. Summary Treatment strategy trials have demonstrated that in the majority of patients with rheumatoid arthritis, the following approach is the most beneficial: goal-steered, dynamic treatment towards tight control of disease activity, including early introduction of (an) effective disease-modifying antirheumatic drug(s) in combination with prednisone or antitumor necrosis factor, which includes tapering of the medication if remission or low disease activity is achieved

AB - Purpose of review To give an overview of recent strategy trials for the treatment of rheumatoid arthritis. Recent findings Strategy studies showed a clear benefit of dynamic result-driven treatment towards tight control of disease activity compared with 'usual care' in rheumatoid arthritis patients. In addition, treatment given after short symptom duration gives better outcomes than later initiation of treatment. In many trials, combination therapies, especially combinations with prednisolone or biologicals, were superior to monotherapies. Moreover, combination therapies were more effective if given early in the disease as compared with a delayed introduction, giving support to the window of opportunity hypothesis. In the BeSt study, initial combination therapy could be successfully discontinued in half. of the patients, emphasizing that 'initial' would mean 'temporary'. Less evidence is available about initial combination in comparison with combination therapy with a shorter delay. Larger tight-controlled, goal-steered, dynamic strategy trials comparing initial combination therapy with a short-delay combination therapy will help to translate the use of initial (temporary) combination therapy into normal daily practice. Summary Treatment strategy trials have demonstrated that in the majority of patients with rheumatoid arthritis, the following approach is the most beneficial: goal-steered, dynamic treatment towards tight control of disease activity, including early introduction of (an) effective disease-modifying antirheumatic drug(s) in combination with prednisone or antitumor necrosis factor, which includes tapering of the medication if remission or low disease activity is achieved

U2 - 10.1097/BOR.0b013e32832a2f1c

DO - 10.1097/BOR.0b013e32832a2f1c

M3 - Article

VL - 21

SP - 291

EP - 298

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -